Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Abbott Laboratories

Stock Market Today: S&P 500, Nasdaq Futures Rise— Bank Of America, Morgan Stanley, Abbott Earnings In Focus (UPDATED)

Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the latest economic releases were updated in the story.

Benzinga

Abbott Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abbott Laboratories (NYSE:ABT) will release earnings results for the third quarter, before the opening bell on Wednesday, Oct. 15.

Benzinga

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Expect From Abbott Laboratories' Next Quarterly Earnings Report

Abbott Laboratories will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart

How Is Abbott Laboratories' Stock Performance Compared to Other Medical Devices Stocks?

Although Abbott Laboratories has underperformed its industry peers recently, analysts remain highly optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb or Sink?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Worried About a Stock Market Crash? These Dividend Stocks Can Help You Ride It Out

Discover four recession-resistant dividend stocks from stable sectors with decades of payout growth, low payout ratios, and strong analyst ratings.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Dividend Stocks With 100+ Years of History and Sky-High Growth

These three century-old companies boast strong buy ratings, 50%+ dividend growth, and rock-solid fundamentals—ideal picks for long-term income investors.

Barchart

Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield

Abbott Laboratories' dividend is safe, the pipeline is strong, and the outlook for growth is positive, making the July price dip a buying opportunity.

MarketBeat

These Analysts Revise Their Forecasts On Abbott Following Q2 Results

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.

Benzinga

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.

Benzinga

Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Abbott Laboratories (NYSE:ABT) will release earnings results for the second quarter, before the opening bell on Thursday, July 17.

Benzinga

Forget Chasing Yields: These 3 Dividend Stocks Are Built to Last

Three top dividend growth stocks have strong fundamentals, analyst buy ratings, and decades of increases, found using Barchart’s free tool.

Barchart

3 Overlooked Dividend Aristocrats To Buy in 2025

These three dividend companies all share one common trait: strong earnings growth and rising cash flow.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

Barchart

What to Expect From Abbott Laboratories' Q2 2025 Earnings Report

Abbott is poised to release its second-quarter results next month, and analysts project a single-digit earnings growth.

Barchart

3 Under-The-Radar Dividend Aristocrats Set to Breakout in Q3

These three dividend companies all share one commonality: near-perfect buy ratings and breakout potential.

Barchart

3 Dirt-Cheap Dividend Aristocrats About to Explode Higher

These buy-rated Dividend Aristocrats are trading at rare discounts, offering strong yields, bullish ratings, and potential long-term upside.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 Dividend Growth Stocks To Buy and Hold Forever

These three companies have a high 5-year dividend yield, providing long-term stability while maximizing income.

Barchart

3 Dividend Aristocrats With Explosive Earnings and Bulletproof Payouts

Discover 3 Dividend Aristocrats with high earnings growth, low payout ratios, and strong analyst ratings: perfect for long-term income investors.

Barchart

Abbott Laboratories Stock: Is ABT Outperforming the Health Care Sector?

Abbott Laboratories has outperformed the Health Care sector over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

The 3 Most Powerful Dividend Kings You’ve Probably Overlooked

These three Dividend Kings have strong cash flow and EPS growth, making a compelling case for long-term income investors.

Barchart

3 Dividend Aristocrats Quietly Dominating The Market in 2025

These three dividend stocks easily beat the S&P 500's return in 2025 while offering predictable earnings and dividend growth.

Barchart

3 Oversold Dividend Aristocrats Wall Street Says Are Ready to Rally

Markets rise on improving geopolitical sentiment, leaving some quality dividend stocks to remain oversold.

Barchart

Is Wall Street Bullish or Bearish on Abbott Laboratories Stock?

As Abbott Laboratories has outperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.